Titre : Chimiokine CCL2

Chimiokine CCL2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Single-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chimiokine CCL2 : Questions médicales les plus fréquentes", "headline": "Chimiokine CCL2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chimiokine CCL2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-26", "dateModified": "2025-02-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chimiokine CCL2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines chimioattractives monocytaires", "url": "https://questionsmedicales.fr/mesh/D018945", "about": { "@type": "MedicalCondition", "name": "Protéines chimioattractives monocytaires", "code": { "@type": "MedicalCode", "code": "D018945", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.110.990" } } }, "about": { "@type": "MedicalCondition", "name": "Chimiokine CCL2", "alternateName": "Chemokine CCL2", "code": { "@type": "MedicalCode", "code": "D018932", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nidhi Joshi", "url": "https://questionsmedicales.fr/author/Nidhi%20Joshi", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India." } }, { "@type": "Person", "name": "Krishna Mohan Poluri", "url": "https://questionsmedicales.fr/author/Krishna%20Mohan%20Poluri", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in." } }, { "@type": "Person", "name": "Nupur Nagar", "url": "https://questionsmedicales.fr/author/Nupur%20Nagar", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India." } }, { "@type": "Person", "name": "Élora Midavaine", "url": "https://questionsmedicales.fr/author/%C3%89lora%20Midavaine", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca." } }, { "@type": "Person", "name": "Philippe Sarret", "url": "https://questionsmedicales.fr/author/Philippe%20Sarret", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis.", "datePublished": "2023-01-03", "url": "https://questionsmedicales.fr/article/36596632", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-061539" } }, { "@type": "ScholarlyArticle", "name": "Focal vibration of the plantarflexor and dorsiflexor muscles improves poststroke spasticity: a randomized single-blind controlled trial.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/35940478", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.rehab.2022.101670" } }, { "@type": "ScholarlyArticle", "name": "Comparison of the Quality of Discharge Letters Written by Large Language Models and Junior Clinicians: Single-Blinded Study.", "datePublished": "2024-07-24", "url": "https://questionsmedicales.fr/article/39047282", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/57721" } }, { "@type": "ScholarlyArticle", "name": "Effect of sweetened beverages intake on salivary aspartame, insulin and alpha-amylase levels: A single-blind study.", "datePublished": "2023-08-28", "url": "https://questionsmedicales.fr/article/37803739", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.foodres.2023.113406" } }, { "@type": "ScholarlyArticle", "name": "The effects of supervision on the outcomes of exercise training in patients with ankylosing spondylitis: A single-blind randomized controlled trial.", "datePublished": "2023-04-25", "url": "https://questionsmedicales.fr/article/37096931", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1756-185X.14711" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Chimiokines", "item": "https://questionsmedicales.fr/mesh/D018925" }, { "@type": "ListItem", "position": 6, "name": "Chimiokines CC", "item": "https://questionsmedicales.fr/mesh/D019742" }, { "@type": "ListItem", "position": 7, "name": "Protéines chimioattractives monocytaires", "item": "https://questionsmedicales.fr/mesh/D018945" }, { "@type": "ListItem", "position": 8, "name": "Chimiokine CCL2", "item": "https://questionsmedicales.fr/mesh/D018932" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chimiokine CCL2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chimiokine CCL2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chimiokine CCL2", "description": "Comment mesurer les niveaux de CCL2 ?\nQuels tests sont utilisés pour évaluer l'inflammation ?\nCCL2 est-il un biomarqueur de maladies ?\nComment CCL2 est-il lié à la maladie cardiovasculaire ?\nPeut-on détecter CCL2 dans le liquide céphalorachidien ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chimiokine CCL2", "description": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?\nCCL2 est-il lié à des symptômes neurologiques ?\nComment CCL2 affecte-t-il le système immunitaire ?\nDes niveaux de CCL2 peuvent-ils causer de la douleur ?\nCCL2 est-il impliqué dans des maladies respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chimiokine CCL2", "description": "Comment réduire les niveaux de CCL2 ?\nLe stress influence-t-il CCL2 ?\nY a-t-il des aliments qui réduisent CCL2 ?\nL'exercice physique affecte-t-il CCL2 ?\nLa qualité du sommeil influence-t-elle CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chimiokine CCL2", "description": "Quels traitements ciblent CCL2 ?\nCCL2 peut-il être une cible pour des thérapies anticancéreuses ?\nComment les anti-inflammatoires affectent-ils CCL2 ?\nY a-t-il des traitements naturels pour CCL2 ?\nLes corticostéroïdes influencent-ils CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chimiokine CCL2", "description": "Quelles complications sont liées à CCL2 ?\nCCL2 est-il impliqué dans des maladies neurodégénératives ?\nComment CCL2 affecte-t-il le diabète ?\nY a-t-il des risques d'infection liés à CCL2 ?\nCCL2 est-il lié à des troubles auto-immuns ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chimiokine CCL2", "description": "Quels facteurs augmentent CCL2 ?\nL'âge influence-t-il les niveaux de CCL2 ?\nLes infections chroniques affectent-elles CCL2 ?\nLe régime alimentaire influence-t-il CCL2 ?\nLe manque d'exercice est-il un facteur de risque pour CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Single-Blind+Method&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer les niveaux de CCL2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de CCL2 peuvent être mesurés par des tests ELISA dans le sérum ou les tissus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'inflammation ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme la CRP et la mesure de CCL2 aident à évaluer l'inflammation." } }, { "@type": "Question", "name": "CCL2 est-il un biomarqueur de maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est un biomarqueur potentiel pour des maladies inflammatoires et auto-immunes." } }, { "@type": "Question", "name": "Comment CCL2 est-il lié à la maladie cardiovasculaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 sont associés à l'inflammation dans les maladies cardiovasculaires." } }, { "@type": "Question", "name": "Peut-on détecter CCL2 dans le liquide céphalorachidien ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 peut être détecté dans le liquide céphalorachidien, indiquant une inflammation neurologique." } }, { "@type": "Question", "name": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent entraîner des symptômes d'inflammation comme douleur et fatigue." } }, { "@type": "Question", "name": "CCL2 est-il lié à des symptômes neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est impliqué dans des symptômes neurologiques dans des maladies comme la sclérose en plaques." } }, { "@type": "Question", "name": "Comment CCL2 affecte-t-il le système immunitaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "CCL2 attire les monocytes et les lymphocytes, influençant la réponse immunitaire." } }, { "@type": "Question", "name": "Des niveaux de CCL2 peuvent-ils causer de la douleur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 peut contribuer à la douleur en favorisant l'inflammation dans les tissus." } }, { "@type": "Question", "name": "CCL2 est-il impliqué dans des maladies respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est associé à des maladies respiratoires comme l'asthme et la BPCO." } }, { "@type": "Question", "name": "Comment réduire les niveaux de CCL2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider." } }, { "@type": "Question", "name": "Le stress influence-t-il CCL2 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de CCL2 et l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des aliments qui réduisent CCL2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des aliments riches en antioxydants, comme les baies, peuvent aider à réduire CCL2." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il CCL2 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut diminuer les niveaux de CCL2 et améliorer la santé globale." } }, { "@type": "Question", "name": "La qualité du sommeil influence-t-elle CCL2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un sommeil de qualité peut réduire l'inflammation et les niveaux de CCL2 dans le corps." } }, { "@type": "Question", "name": "Quels traitements ciblent CCL2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de CCL2 sont en développement pour traiter des maladies inflammatoires." } }, { "@type": "Question", "name": "CCL2 peut-il être une cible pour des thérapies anticancéreuses ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, cibler CCL2 pourrait aider à réduire l'infiltration tumorale et l'inflammation." } }, { "@type": "Question", "name": "Comment les anti-inflammatoires affectent-ils CCL2 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les anti-inflammatoires peuvent réduire les niveaux de CCL2 et atténuer l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour CCL2 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent moduler les niveaux de CCL2, mais des études sont nécessaires." } }, { "@type": "Question", "name": "Les corticostéroïdes influencent-ils CCL2 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire l'expression de CCL2 dans les tissus inflammés." } }, { "@type": "Question", "name": "Quelles complications sont liées à CCL2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent entraîner des complications dans les maladies cardiovasculaires." } }, { "@type": "Question", "name": "CCL2 est-il impliqué dans des maladies neurodégénératives ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est associé à des complications dans des maladies comme Alzheimer et Parkinson." } }, { "@type": "Question", "name": "Comment CCL2 affecte-t-il le diabète ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "CCL2 peut contribuer à l'inflammation et aux complications associées au diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques d'infection liés à CCL2 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent augmenter le risque d'infections en favorisant l'inflammation." } }, { "@type": "Question", "name": "CCL2 est-il lié à des troubles auto-immuns ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est impliqué dans des complications de troubles auto-immuns comme la polyarthrite." } }, { "@type": "Question", "name": "Quels facteurs augmentent CCL2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, l'obésité et le stress sont des facteurs de risque augmentant CCL2." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux de CCL2 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de CCL2 tendent à augmenter avec l'âge, contribuant à l'inflammation." } }, { "@type": "Question", "name": "Les infections chroniques affectent-elles CCL2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections chroniques peuvent augmenter les niveaux de CCL2 dans le corps." } }, { "@type": "Question", "name": "Le régime alimentaire influence-t-il CCL2 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un régime riche en graisses saturées peut augmenter les niveaux de CCL2 et l'inflammation." } }, { "@type": "Question", "name": "Le manque d'exercice est-il un facteur de risque pour CCL2 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le manque d'exercice peut contribuer à des niveaux élevés de CCL2 et à l'inflammation." } } ] } ] }

Sources (10000 au total)

Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis.

There is an urgent need for remyelinating therapies that restore function in people with multiple sclerosis (pwMS). Aerobic exercise is a promising remyelinating strategy because it promotes remyelina... Sedentary participants (n=60; aged 18-64 years) with stable MS will undergo a baseline visit with the following outcomes to assess associations between demyelination and mobility (part 1): spinal cord... Ethical approval was obtained from the Oregon Health & Science University Institutional Review Board (#21045). Dissemination of findings will include peer-reviewed publications, conference presentatio... NCT04539002....

Focal vibration of the plantarflexor and dorsiflexor muscles improves poststroke spasticity: a randomized single-blind controlled trial.

Post-stroke spasticity is a cause of gait dysfunction and disability. Focal vibration (FV) of agonist-antagonist upper limb muscle pairs reduces flexor spasticity; however, its effects on ankle planta... To assess the effects of focal vibration administered by a trained operator to the ankle plantarflexor and dorsiflexor muscles on post-stroke lower limb spasticity.... A randomized, single-blind controlled trial of 64 participants with stroke and plantarflexor spasticity assigned to 3 groups by centralized, computer-generated randomization (1:1:1): 1) physiotherapy ... MAS remission rate was higher in FV_GM and FV_TA than CON groups (CON vs. FV_GM: p=0.009, odds ratio 0.15 [95% confidence interval 0.03-0.67]; CON vs. FV_TA: p=0.002, 0.12 [0.03-0.51]). Remission rate... Focal vibration reduced post-stroke spasticity of the plantarflexor muscles. Vibration of the tibialis anterior improved ambulation more than vibration of the gastrocnemius or physiotherapy alone. Gas...

Comparison of the Quality of Discharge Letters Written by Large Language Models and Junior Clinicians: Single-Blinded Study.

Discharge letters are a critical component in the continuity of care between specialists and primary care providers. However, these letters are time-consuming to write, underprioritized in comparison ... The aim of this study was to assess the performance of GPT-4 in generating discharge letters written from urology specialist outpatient clinics to primary care providers and to compare their quality a... Fictional electronic records were written by physicians simulating 5 common urology outpatient cases with long-term follow-up. Records comprised simulated consultation notes, referral letters and repl... GPT-4 outperformed human counterparts in information provision (mean 4.32, SD 0.95 vs 3.70, SD 1.27; P=.03) and had no instances of hallucination. There were no statistically significant differences i... Discharge letters written by GPT-4 had equivalent quality to those written by junior clinicians, without any hallucinations. This study provides a proof of concept that large language models can be us...

The effects of supervision on the outcomes of exercise training in patients with ankylosing spondylitis: A single-blind randomized controlled trial.

Exercise training is crucial for managing ankylosing spondylitis. We evaluated the effects of exercise with different levels of supervision on clinical outcomes in patients with ankylosing spondylitis... We performed a single-blind randomized controlled trial in a university outpatient clinic. Overall, 45 (31 men) patients with ankylosing spondylitis were randomly allocated to 3 groups. The mean (SD) ... Within-group analysis showed significant improvement in chest expansion (P = 0.016) and all subjective or objective questionnaire scores (all P < 0.001) for the full-supervised group. Between-group an... We recommend the prescription of a supervised training program instead of in-home exercises for patients with ankylosing spondylitis....

Effect of Ischemic Preconditioning on Acute Recovery in Elite Judo Athletes: A Randomized, Single-Blind, Crossover Trial.

The ischemic preconditioning (IPC) method has been shown to aid the recovery processes; however, no studies have been done to assess its acute recovery use in judo. This study aimed to examine IPC of ... A single-blind, placebo-randomized crossover study was carried out on a sample of 13 elite male judo athletes. They undertook measurements of body composition, judo-specific task (Special Judo Fitness... The IPC intervention resulted in (1) decreased heart rate at 30 and 60 minutes during recovery (P = .002; P = .001), (2) better countermovement jump performance at 60 minutes (P = .05), (3) lower perc... The present study revealed that IPC applied to judo athletes following judo-specific exercise resulted in better cardiovascular and neuromuscular recovery and could be a useful tool to enhance recover...

Bleaching efficacy of in-office dental bleaching with different application protocols: a single-blind randomized controlled trial.

This randomized controlled trial aimed to evaluate the equivalence in the color change, adverse effects, self-perception (AS) and the impact on oral condition (IO) of participants submitted to differe... 165 participants were bleached with a 35% hydrogen peroxide gel (Total Blanc Office One-Step, DFL), according to the following protocols: (1) 2 applications of 20-min each (2 × 20 min); (2) 1 × 40-min... Equivalent color change were observed (p < 0.001), with no significant difference between groups. The group 2 × 20 min presented the highest risk of TS (76%, 95% CI 63 to 85), compared to the 1 × 30 m... The 1 × 30 min protocol produced equivalent color change to the other bleaching protocols with reduced risk of TS and shorter application time.... A more simplified application regimen of a single application of 30 min yields effective bleaching and patient satisfaction while minimizing undesirable side effects and improving patient satisfaction...

Efficacy of a buccal and lingual at-home bleaching protocol-A randomized, split-mouth, single-blind controlled trial.

To compare the color change, the risk and intensity of tooth sensitivity (TS), and gingival irritation (GI) of at-home bleaching applied on the buccal surface only or the buccal and lingual surfaces.... Sixty patients with canines A... Neither the color change nor the risk/intensity of TS was statistically different between groups (p > 0.05). Patient satisfaction increased after bleaching for both groups (p < 0.05).... The addition of one contact surface does not result in an increased whitening degree compared to bleaching applied solely on the buccal surface.... Understanding the influence of surfaces interacting with the bleaching agent is crucial for comprehending the bleaching mechanism and avoiding unnecessary material expenses. Notably, employing the buc...

Efficacy of interactive manual dexterity training after stroke: a pilot single-blinded randomized controlled trial.

To compare the efficacy of Dextrain Manipulandum™ training of dexterity components such as force control and independent finger movements, to dose-matched conventional therapy (CT) post-stroke.... A prospective, single-blind, pilot randomized clinical trial was conducted. Chronic-phase post-stroke patients with mild-to-moderate dexterity impairment (Box and Block Test (BBT) > 1) received 12 ses... BBT-change after training did not differ between the Dextrain (N = 21) vs CT group (N = 21) (median [IQR] = 5[2-7] vs 4[2-7], respectively; P = 0.36). Gains in BBT were maintained at the 3-month post-... Although immediate improvements in gross dexterity post-stroke did not significantly differ between Dextrain training and CT, our findings suggest that Dextrain enhances recovery of several dexterity ...